Floatz logo

Anti-Cd19/20-Car Vector-Transduced T Cells

B-cell Leukemia

University Hospital, Basel, SwitzerlandCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

2 Active assets in the B-cell Leukemia cohort.

Asset / SponsorPhaseRating
4scar-cd22/cd123/cd38/cd10/cd20/tslpr
Shenzhen Geno-Immune Medical Institute
Phase 1/2CC
cd19/cd20 dual-car-t cells
Hebei Yanda Ludaopei Hospital
Phase 1CC
Kur-502
Athenex, Inc.
Phase 1CC

Same molecule, other indications

Anti-Cd19/20-Car Vector-Transduced T Cells is also rated in:

B Cell LymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
Hematopoietic/Lymphoid CancerDormant
CCC
Indicative ·
52 / 100
View asset →
Adult Acute Lymphoblastic Leukemia in RemissionDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →